Désiré Collen

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Collen D; Lijnen H R
The tissue-type plasminogen activator story.
Peeters Karen; Stassen Jean-Marie; Collen Désiré; Van Geet Chris; Freson Kathleen
Emerging treatments for thrombocytopenia: increasing platelet production.
Marsboom Glenn; Pokreisz Peter; Gheysens Olivier; Vermeersch Pieter; Gillijns Hilde; Pellens Marijke; Liu Xiaoshun; Collen Désiré; Janssens Stefan
Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Désiré Collen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Collen D; Lijnen H R
The tissue-type plasminogen activator story.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(8):1151-5.
2008: Peeters Karen; Stassen Jean-Marie; Collen Désiré; Van Geet Chris; Freson Kathleen
Emerging treatments for thrombocytopenia: increasing platelet production.
Drug discovery today 2008;13(17-18):798-806.
2008: Marsboom Glenn; Pokreisz Peter; Gheysens Olivier; Vermeersch Pieter; Gillijns Hilde; Pellens Marijke; Liu Xiaoshun; Collen Désiré; Janssens Stefan
Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension.
Stem cells (Dayton, Ohio) 2008;26(4):1017-26.
2008: Angelillo-Scherrer Anne; Burnier Laurent; Lambrechts Diether; Fish Richard J; Tjwa Marc; Plaisance Stéphane; Sugamele Rocco; DeMol Maria; Martinez-Soria Eduardo; Maxwell Patrick H; Lemke Greg; Goff Stephen P; Matsushima Glenn K; Earp H Shelton; Chanson Marc; Collen Désiré; Izui Shozo; Schapira Marc; Conway Edward M; Carmeliet Peter
Role of Gas6 in erythropoiesis and anemia in mice.
The Journal of clinical investigation 2008;118(2):583-96.
2007: Fischer Christian; Jonckx Bart; Mazzone Massimiliano; Zacchigna Serena; Loges Sonja; Pattarini Lucia; Chorianopoulos Emmanuel; Liesenborghs Laurens; Koch Marta; De Mol Maria; Autiero Monica; Wyns Sabine; Plaisance Stephane; Moons Lieve; van Rooijen Nico; Giacca Mauro; Stassen Jean-Marie; Dewerchin Mieke; Collen Desire; Carmeliet Peter
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
Cell 2007;131(3):463-75.
2007: Lijnen H R; Van Hoef B; Kemp D; Collen D
Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity.
Biochimica et biophysica acta 2007;1770(9):1369-73.
2007: Vermeersch Pieter; Buys Emmanuel; Pokreisz Peter; Marsboom Glenn; Ichinose Fumito; Sips Patrick; Pellens Marijke; Gillijns Hilde; Swinnen Marc; Graveline Amanda; Collen Desire; Dewerchin Mieke; Brouckaert Peter; Bloch Kenneth D; Janssens Stefan
Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
Circulation 2007;116(8):936-43.
2007: Suzuki Y; Nagai N; Umemura K; Collen D; Lijnen H R
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.
Journal of thrombosis and haemostasis : JTH 2007;5(8):1732-9.
2007: Verhamme Peter; Goossens Godelieve; Maleux Geert; Collen Désiré; Stas Marguerite
A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion.
Journal of thrombosis and thrombolysis 2007;24(1):1-5.
2007: Zwerts Femke; Lupu Florea; De Vriese Astrid; Pollefeyt Saskia; Moons Lieve; Altura Rachel A; Jiang Yuying; Maxwell Patrick H; Hill Peter; Oh Hideyasu; Rieker Claus; Collen Désiré; Conway Simon J; Conway Edward M
Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure.
Blood 2007;109(11):4742-52.
2007: Snoeys J; Lievens J; Wisse E; Jacobs F; Duimel H; Collen D; Frederik P; De Geest B
Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae.
Gene therapy 2007;14(7):604-12.
2007: Vandendriessche T; Thorrez L; Acosta-Sanchez A; Petrus I; Wang L; Ma L; DE Waele L; Iwasaki Y; Gillijns V; Wilson J M; Collen D; Chuah M K L
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy.
Journal of thrombosis and haemostasis : JTH 2007;5(1):16-24.
2006: Lijnen H Roger; Alessi Marie-Christine; Frederix Liesbeth; Collen Désiré; Juhan-Vague Irène
Tiplaxtinin impairs nutritionally induced obesity in mice.
Thrombosis and haemostasis 2006;96(6):731-7.
2006: Voros Gabor; Sandy John D; Collen Désiré; Lijnen H Roger
Expression of aggrecan(ases) during murine preadipocyte differentiation and adipose tissue development.
Biochimica et biophysica acta 2006;1760(12):1837-44.
2006: Lijnen H Roger; Christiaens Valerie; Scroyen Ilse; Voros Gabor; Tjwa Marc; Carmeliet Peter; Collen Désiré
Impaired adipose tissue development in mice with inactivation of placental growth factor function.
Diabetes 2006;55(10):2698-704.
2006: Thorrez Lieven; Vandenburgh Herman; Callewaert Nico; Mertens Nico; Shansky Janet; Wang Lin; Arnout Jef; Collen Désiré; Chuah Marinee; Vandendriessche Thierry
Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(3):442-51.
2006: Van de Wouwer M; Plaisance S; De Vriese A; Waelkens E; Collen D; Persson J; Daha M R; Conway E M
The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.
Journal of thrombosis and haemostasis : JTH 2006;4(8):1813-24.
2006: Demeulemeester Diego; Scroyen Ilse; Voros Gabor; Snoeys Jan; De Geest Bart; Collen Désiré; Lijnen H Roger
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development.
Thrombosis and haemostasis 2006;95(6):1019-24.
2006: De Meyer Simon F; Vanhoorelbeke Karen; Chuah Marinee K; Pareyn Inge; Gillijns Veerle; Hebbel Robert P; Collen Désiré; Deckmyn Hans; VandenDriessche Thierry
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.
Blood 2006;107(12):4728-36.
2006: Jacquemin M; Radcliffe C M; Lavend'homme R; Wormald M R; Vanderelst L; Wallays G; Dewaele J; Collen D; Vermylen J; Dwek R A; Saint-Remy J-M; Rudd P M; Dewerchin M
Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody.
Journal of thrombosis and haemostasis : JTH 2006;4(5):1047-55.
2006: Pokreisz Peter; Fleming Ingrid; Kiss Ladislau; Barbosa-Sicard Eduardo; Fisslthaler Beate; Falck John R; Hammock Bruce D; Kim In-Hae; Szelid Zsolt; Vermeersch Pieter; Gillijns Hilde; Pellens Marijke; Grimminger Friedrich; van Zonneveld Anton-Jan; Collen Desire; Busse Rudi; Janssens Stefan
Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling.
Hypertension 2006;47(4):762-70.
2006: Van Damme An; Thorrez Lieven; Ma Ling; Vandenburgh Herman; Eyckmans Jeroen; Dell'Accio Francesco; De Bari Cosimo; Luyten Frank; Lillicrap David; Collen Désiré; VandenDriessche Thierry; Chuah Marinee K L
Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells.
Stem cells (Dayton, Ohio) 2006;24(4):896-907.
2006: Rossignol P; Luttun A; Martin-Ventura J L; Lupu F; Carmeliet P; Collen D; Anglès-Cano E; Lijnen H R
Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.
Journal of thrombosis and haemostasis : JTH 2006;4(3):664-70.
2006: Semeraro Fabrizio; Voros Gabor; Collen Désiré; Lijnen H Roger
Impairment of adipose tissue development by hypoxia is not mediated by plasminogen activator inhibitor-1.
Thrombosis and haemostasis 2006;95(1):174-81.
2006: Snoeys Jan; Mertens Geertrui; Lievens Joke; van Berkel Theo; Collen Désiré; Biessen Erik A L; De Geest Bart
Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13(1):98-107.
2005: De Geest Bart; Snoeys Jan; Van Linthout Sophie; Lievens Joke; Collen Désiré
Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone.
Human gene therapy 2005;16(12):1439-51.
2005: Voros Gabor; Maquoi Erik; Demeulemeester Diego; Clerx Natalie; Collen Désiré; Lijnen H Roger
Modulation of angiogenesis during adipose tissue development in murine models of obesity.
Endocrinology 2005;146(10):4545-54.
2005: Ny Annelii; Koch Marta; Schneider Martin; Neven Elke; Tong Ricky T; Maity Sunit; Fischer Christian; Plaisance Stephane; Lambrechts Diether; Héligon Christophe; Terclavers Sven; Ciesiolka Malgorzata; Kälin Roland; Man Wing Yan; Senn Irena; Wyns Sabine; Lupu Florea; Brändli André; Vleminckx Kris; Collen Désiré; Dewerchin Mieke; Conway Edward M; Moons Lieve; Jain Rakesh K; Carmeliet Peter
A genetic Xenopus laevis tadpole model to study lymphangiogenesis.
Nature medicine 2005;11(9):998-1004.
2005: Acker Till; Diez-Juan Antonio; Aragones Julian; Tjwa Marc; Brusselmans Koen; Moons Lieve; Fukumura Dai; Moreno-Murciano Maria Paz; Herbert Jean-Marc; Burger Angelika; Riedel Johanna; Elvert Gerd; Flamme Ingo; Maxwell Patrick H; Collen Désiré; Dewerchin Mieke; Jain Rakesh K; Plate Karl H; Carmeliet Peter
Genetic evidence for a tumor suppressor role of HIF-2alpha.
Cancer cell 2005;8(2):131-41.
2005: Nagai N; Suzuki Y; Van Hoef B; Lijnen H R; Collen D
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.
Journal of thrombosis and haemostasis : JTH 2005;3(7):1379-84.
2005: Melis Els; Moons Lieve; Arnout Jef; Hoylaerts Marc F; Collen Désiré; Carmeliet Peter; Dewerchin Mieke
Thrombophilia in mice expressing a tissue factor variant lacking its transmembrane and cytosolic domain.
Biochemical and biophysical research communications 2005;333(2):488-95.
2005: Lijnen H R; Alessi M-C; Van Hoef B; Collen D; Juhan-Vague I
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice.
Journal of thrombosis and haemostasis : JTH 2005;3(6):1174-9.
2005: Khurana Rohit; Moons Lieve; Shafi Shahida; Luttun Aernout; Collen Désiré; Martin John F; Carmeliet Peter; Zachary Ian C
Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation.
Circulation 2005;111(21):2828-36.
2005: Rossenbacker T; Schollen E; Kuipéri C; de Ravel T J L; Devriendt K; Matthijs G; Collen D; Heidbüchel H; Carmeliet P
Unconventional intronic splice site mutation in SCN5A associates with cardiac sodium channelopathy.
Journal of medical genetics 2005;42(5):e29.
2005: Collen Désiré; Hoylaerts Marc F
Relationship between inflammation and venous thromboembolism as studied by microparticle assessment in plasma.
Journal of the American College of Cardiology 2005;45(9):1472-3.
2005: Maquoi Erik; Vörös Gabor; Carmeliet Peter; Collen Désiré; Lijnen H Roger
Role of Gas-6 in adipogenesis and nutritionally induced adipose tissue development in mice.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(5):1002-7.
2005: Collen Désiré; Lijnen H Roger
Thrombolytic agents.
Thrombosis and haemostasis 2005;93(4):627-30.
2005: Demeulemeester Diego; Collen Désiré; Lijnen H Roger
Effect of matrix metalloproteinase inhibition on adipose tissue development.
Biochemical and biophysical research communications 2005;329(1):105-10.
2005: Rossenbacker Tom; Mubagwa Kanigula; Jongbloed Roselie J; Vereecke Johan; Devriendt Koen; Gewillig Marc; Carmeliet Edward; Collen Désiré; Heidbüchel Hein; Carmeliet Peter
Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome.
Circulation 2005;111(8):961-8.
2005: Angelillo-Scherrer Anne; Burnier Laurent; Flores Nathalie; Savi Pierre; DeMol Maria; Schaeffer Paul; Herbert Jean-Marc; Lemke Greg; Goff Stephen P; Matsushima Glenn K; Earp H Shelton; Vesin Christian; Hoylaerts Marc F; Plaisance Stéphane; Collen Désiré; Conway Edward M; Wehrle-Haller Bernhard; Carmeliet Peter
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy.
The Journal of clinical investigation 2005;115(2):237-46.
2005: Brusselmans Koen; Bono Françoise; Collen Désiré; Herbert Jean-Marc; Carmeliet Peter; Dewerchin Mieke
A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia.
The Journal of biological chemistry 2005;280(5):3493-9.
2005: Heymans Stephane; Lupu Florea; Terclavers Sven; Vanwetswinkel Bjorn; Herbert Jean-Marc; Baker Andrew; Collen Desire; Carmeliet Peter; Moons Lieve
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.
The American journal of pathology 2005;166(1):15-25.
2005: Li Xuri; Tjwa Marc; Moons Lieve; Fons Pierre; Noel Agnes; Ny Annelii; Zhou Jian Min; Lennartsson Johan; Li Hong; Luttun Aernout; Pontén Annica; Devy Laetitia; Bouché Ann; Oh Hideyasu; Manderveld Ann; Blacher Silvia; Communi David; Savi Pierre; Bono Françoise; Dewerchin Mieke; Foidart Jean-Michel; Autiero Monica; Herbert Jean-Marc; Collen D; Heldin Carl-Henrik; Eriksson Ulf; Carmeliet Peter
Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors.
The Journal of clinical investigation 2005;115(1):118-27.
2005: Storkebaum Erik; Lambrechts Diether; Dewerchin Mieke; Moreno-Murciano Maria-Paz; Appelmans Saskia; Oh Hideyasu; Van Damme Philip; Rutten Bart; Man Wing Yan; De Mol Maria; Wyns Sabine; Manka David; Vermeulen Kristel; Van Den Bosch Ludo; Mertens Nico; Schmitz Christoph; Robberecht Wim; Conway Edward M; Collen Désiré; Moons Lieve; Carmeliet Peter
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.
Nature neuroscience 2005;8(1):85-92.
2004: Chuah M K L; Collen D; Vandendriessche T
Preclinical and clinical gene therapy for haemophilia.
Haemophilia : the official journal of the World Federation of Hemophilia 2004;10 Suppl 4():119-25.
2004: Suzuki Yasuhiro; Chen Feng; Ni Yicheng; Marchal Guy; Collen Desire; Nagai Nobuo
Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI.
Stroke; a journal of cerebral circulation 2004;35(10):2402-6.
2004: Lievens J; Snoeys J; Vekemans K; Van Linthout S; de Zanger R; Collen D; Wisse E; De Geest B
The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer.
Gene therapy 2004;11(20):1523-31.
2004: Suzuki Y; Nagai N; Collen D
Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice.
Journal of thrombosis and haemostasis : JTH 2004;2(9):1617-21.
2004: Van de Wouwer Marlies; Collen Désiré; Conway Edward M
Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(8):1374-83.
2004: Janssens Stefan; Pokreisz Peter; Schoonjans Luc; Pellens Marijke; Vermeersch Pieter; Tjwa Marc; Jans Peter; Scherrer-Crosbie Marielle; Picard Michael H; Szelid Zsolt; Gillijns Hilde; Van de Werf Frans; Collen Desire; Bloch Kenneth D
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.
Circulation research 2004;94(9):1256-62.
2004: Chuah Marinee K; Collen Désiré; VandenDriessche Thierry
Clinical gene transfer studies for hemophilia A.
Seminars in thrombosis and hemostasis 2004;30(2):249-56.
2004: Van Damme An; Chuah Marinee K L; Collen Désiré; VandenDriessche Thierry
Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
Seminars in thrombosis and hemostasis 2004;30(2):185-95.
2004: Thorrez Lieven; VandenDriessche Thierry; Collen Désiré; Chuah Marinee K
Preclinical gene therapy studies for hemophilia using adenoviral vectors.
Seminars in thrombosis and hemostasis 2004;30(2):173-83.
2004: Collen D; Lijnen H R
Tissue-type plasminogen activator: a historical perspective and personal account.
Journal of thrombosis and haemostasis : JTH 2004;2(4):541-6.
2004: Voros G; Maquoi E; Collen D; Lijnen H R
Influence of membrane-bound tumor necrosis factor (TNF)-alpha on obesity and glucose metabolism.
Journal of thrombosis and haemostasis : JTH 2004;2(3):507-13.
2004: Luttun Aernout; Lutgens Esther; Manderveld Ann; Maris Katleen; Collen Désiré; Carmeliet Peter; Moons Lieve
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth.
Circulation 2004;109(11):1408-14.
2004: Dewerchin M; Van der Elst L; Singh I; Grailly S; Saint-Remy J-M; Collen D; Jacquemin M
Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice.
Journal of thrombosis and haemostasis : JTH 2004;2(1):77-84.
2004: Lijnen H R; Van Hoef B; Umans K; Collen D
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1).
Journal of thrombosis and haemostasis : JTH 2004;2(1):16-22.
2004: Hochepied Tino; Schoonjans Luc; Staelens Jan; Kreemers Veerle; Danloy Sophie; Puimège Leen; Collen Désiré; Van Roy Frans; Libert Claude
Breaking the species barrier: derivation of germline-competent embryonic stem cells from Mus spretus x C57BL/6 hybrids.
Stem cells (Dayton, Ohio) 2004;22(4):441-7.
2003: Chuah Marinee K L; Collen Désiré; VandenDriessche Thierry
Biosafety of adenoviral vectors.
Current gene therapy 2003;3(6):527-43.
2003: VandenDriessche Thierry; Collen Désiré; Chuah Marinee K L
Biosafety of onco-retroviral vectors.
Current gene therapy 2003;3(6):501-15.
2003: Compernolle Veerle; Brusselmans Koen; Franco Diego; Moorman Antoon; Dewerchin Mieke; Collen Désiré; Carmeliet Peter
Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha.
Cardiovascular research 2003;60(3):569-79.
2003: Dewerchin Mieke; Hérault Jean-Pascal; Wallays Goedele; Petitou Maurice; Schaeffer Paul; Millet Laurence; Weitz Jeffrey I; Moons Lieve; Collen Désiré; Carmeliet Peter; Herbert Jean-Marc
Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin.
Circulation research 2003;93(11):1120-6.
2003: Janssen Anneleen; Gressens Pierre; Grabenbauer Markus; Baumgart Eveline; Schad Arno; Vanhorebeek Ilse; Brouwers Annelies; Declercq Peter E; Fahimi Dariush; Evrard Philippe; Schoonjans Luc; Collen Désiré; Carmeliet Peter; Mannaerts Guy; Van Veldhoven Paul; Baes Myriam
Neuronal migration depends on intact peroxisomal function in brain and in extraneuronal tissues.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2003;23(30):9732-41.
2003: Moreadith Randall W; Collen Désiré
Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction.
Advanced drug delivery reviews 2003;55(10):1337-45.
2003: Conway Edward M; Zwerts Femke; Van Eygen Veerle; DeVriese Astrid; Nagai Nobuo; Luo Wei; Collen Désiré
Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation.
The American journal of pathology 2003;163(3):935-46.
2003: VandenDriessche T; Collen D; Chuah M K L
Gene therapy for the hemophilias.
Journal of thrombosis and haemostasis : JTH 2003;1(7):1550-8.
2003: Autiero Monica; Waltenberger Johannes; Communi Didier; Kranz Andrea; Moons Lieve; Lambrechts Diether; Kroll Jens; Plaisance Stephane; De Mol Maria; Bono Françoise; Kliche Stefanie; Fellbrich Guido; Ballmer-Hofer Kurt; Maglione Domenico; Mayr-Beyrle Ulrike; Dewerchin Mieke; Dombrowski Saskia; Stanimirovic Danica; Van Hummelen Paul; Dehio Christoph; Hicklin Daniel J; Persico Graziella; Herbert Jean-Marc; Communi David; Shibuya Masabumi; Collen Désiré; Conway Edward M; Carmeliet Peter
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.
Nature medicine 2003;9(7):936-43.
2003: Armstrong Paul W; Collen Désiré; Antman Elliott
Fibrinolysis for acute myocardial infarction: the future is here and now.
Circulation 2003;107(20):2533-7.
2003: Brusselmans Koen; Compernolle Veerle; Tjwa Marc; Wiesener Michael S; Maxwell Patrick H; Collen Désiré; Carmeliet Peter
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.
The Journal of clinical investigation 2003;111(10):1519-27.
2003: Maquoi Erik; Demeulemeester Diego; Vörös Gabor; Collen Désire; Lijnen H Roger
Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation.
Thrombosis and haemostasis 2003;89(4):696-704.
2003: De Geest Bart R; Van Linthout Sophie A; Collen Désiré
Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells.
Blood 2003;101(7):2551-6.
2003: Chuah Marinee K L; Schiedner Gudrun; Thorrez Lieven; Brown Brian; Johnston Marion; Gillijns Veerle; Hertel Sabine; Van Rooijen Nico; Lillicrap David; Collen Désiré; VandenDriessche Thierry; Kochanek Stefan
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Blood 2003;101(5):1734-43.
2003: Nagai N; Demarsin E; Van Hoef B; Wouters S; Cingolani D; Laroche Y; Collen D
Recombinant human microplasmin: production and potential therapeutic properties.
Journal of thrombosis and haemostasis : JTH 2003;1(2):307-13.
2003: Janssens Wim; Chuah Marinee K L; Naldini Luigi; Follenzi Antonia; Collen Désiré; Saint-Remy Jean-Marie; VandenDriessche Thierry
Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent.
Human gene therapy 2003;14(3):263-76.
2003: Lijnen H Roger; Demeulemeester Diego; Van Hoef Berthe; Collen Désiré; Maquoi Erik
Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice.
Thrombosis and haemostasis 2003;89(2):249-55.
2003: Van Damme A; Chuah M K L; Dell'accio F; De Bari C; Luyten F; Collen D; VandenDriessche T
Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
Haemophilia : the official journal of the World Federation of Hemophilia 2003;9(1):94-103.
2003: Voros Gabor; Maquoi Erik; Collen Désiré; Lijnen H Roger
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories.
Biochimica et biophysica acta 2003;1625(1):36-42.
2003: Lijnen H Roger; Maquoi Erik; Morange Pierre; Voros Gabor; Van Hoef Berthe; Kopp Francis; Collen Désiré; Juhan-Vague Irène; Alessi Marie-Christine
Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(1):78-84.
2003: Schoonjans Luc; Kreemers Veerle; Danloy Sophie; Moreadith Randall W; Laroche Yves; Collen Désiré
Improved generation of germline-competent embryonic stem cell lines from inbred mouse strains.
Stem cells (Dayton, Ohio) 2003;21(1):90-7.
2002: Szelid Zsolt; Sinnaeve Peter; Vermeersch Pieter; Gillijns Hilde; Pellens Marijke; Laurysens Veerle; Van Pelt Natascha; Flameng Willem; Sergeant Paul; Herijgers Paul; Pokreisz Peter; Van Zonneveld Anton-Jan; Verbeken Erik; Collen Desire; Janssens Stefan
Preexisting antiadenoviral immunity and regional myocardial gene transfer: modulation by nitric oxide.
Human gene therapy 2002;13(18):2185-95.
2002: Praus Michael; Collen Désiré; Gerard Robert D
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
International journal of cancer. Journal international du cancer 2002;102(6):584-91.
2002: Van Linthout S; Lusky M; Collen D; De Geest B
Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Gene therapy 2002;9(22):1520-8.
2002: Conway Edward M; Van de Wouwer Marlies; Pollefeyt Saskia; Jurk Kerstin; Van Aken Hugo; De Vriese Astrid; Weitz Jeffrey I; Weiler Hartmut; Hellings Peter W; Schaeffer Paul; Herbert Jean-Marc; Collen Désiré; Theilmeier Gregor
The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways.
The Journal of experimental medicine 2002;196(5):565-77.
2002: Theilmeier Gregor; Verhamme Peter; Dymarkowski Steven; Beck Heike; Bernar Hilde; Lox Marleen; Janssens Stefan; Herregods Marie-Christine; Verbeken Erik; Collen Désiré; Plate Karl; Flameng Willem; Holvoet Paul
Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary flow reserve and reduced capillary density.
Circulation 2002;106(9):1140-6.
2002: Lijnen H Roger; Maquoi Erik; Demeulemeester Diego; Van Hoef Berthe; Collen Désiré
Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity.
Thrombosis and haemostasis 2002;88(2):345-53.
2002: Conway Edward M; Pollefeyt Saskia; Steiner-Mosonyi Marta; Luo Wei; Devriese Astrid; Lupu Florea; Bono Francoise; Leducq Nathalie; Dol Frederique; Schaeffer Paul; Collen Désiré; Herbert Jean-Marc
Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways.
Gastroenterology 2002;123(2):619-31.
2002: VandenDriessche Thierry; Thorrez Lieven; Naldini Luigi; Follenzi Antonia; Moons Lieve; Berneman Zwi; Collen Desire; Chuah Marinee K L
Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo.
Blood 2002;100(3):813-22.
2002: Theilmeier Gregor; Quarck Rozenn; Verhamme Peter; Bochaton-Piallat Marie Luce; Lox Marleen; Bernar Hilde; Janssens Stefan; Kockx Mark; Gabbiani Giulio; Collen Désiré; Holvoet Paul
Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty.
Cardiovascular research 2002;55(2):385-95.
2002: Luttun Aernout; Tjwa Marc; Moons Lieve; Wu Yan; Angelillo-Scherrer Anne; Liao Fang; Nagy Janice A; Hooper Andrea; Priller Josef; De Klerck Bert; Compernolle Veerle; Daci Evis; Bohlen Peter; Dewerchin Mieke; Herbert Jean-Marc; Fava Roy; Matthys Patrick; Carmeliet Geert; Collen Désiré; Dvorak Harold F; Hicklin Daniel J; Carmeliet Peter
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.
Nature medicine 2002;8(8):831-40.
2002: Luttun Aernout; Brusselmans Koen; Fukao Hideharu; Tjwa Marc; Ueshima Shigeru; Herbert Jean-Marc; Matsuo Osamu; Collen Désiré; Carmeliet Peter; Moons Lieve
Loss of placental growth factor protects mice against vascular permeability in pathological conditions.
Biochemical and biophysical research communications 2002;295(2):428-34.
2002: Compernolle Veerle; Brusselmans Koen; Acker Till; Hoet Peter; Tjwa Marc; Beck Heike; Plaisance Stéphane; Dor Yuval; Keshet Eli; Lupu Florea; Nemery Benoit; Dewerchin Mieke; Van Veldhoven Paul; Plate Karl; Moons Lieve; Collen Désiré; Carmeliet Peter
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice.
Nature medicine 2002;8(7):702-10.
2002: Sinnaeve Peter; Chiche Jean-Daniel; Gillijns Hilde; Van Pelt Natascha; Wirthlin Douglas; Van De Werf Frans; Collen Desire; Bloch Kenneth D; Janssens Stefan
Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis.
Circulation 2002;105(24):2911-6.
2002: Mattot Virginie; Moons Lieve; Lupu Florea; Chernavvsky Daniel; Gómez R Ariel; Collen Désiré; Carmeliet Peter
Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice.
Journal of the American Society of Nephrology : JASN 2002;13(6):1548-60.
2002: Theilmeier Gregor; Michiels Carine; Spaepen Erik; Vreys Ingrid; Collen Désiré; Vermylen Jos; Hoylaerts Marc F
Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia.
Blood 2002;99(12):4486-93.
2002: Van Damme An; Vanden Driessche Thierry; Collen Desire; Chuah Marinee K L
Bone marrow stromal cells as targets for gene therapy.
Current gene therapy 2002;2(2):195-209.
2002: Silence J; Collen D; Lijnen H R
Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene.
Circulation research 2002;90(8):897-903.
2002: Van Linthout Sophie; Collen Désiré; De Geest Bart
Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I.
Human gene therapy 2002;13(7):829-40.
2002: Singh Inderjit; Smith Alberto; Vanzieleghem Beatrijs; Collen Désiré; Burnand Kevin; Saint-Remy Jean-Marie; Jacquemin Marc
Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model.
Blood 2002;99(9):3235-40.
2002: Warmerdam Petra A M; Plaisance Stéphane; Vanderlick Kristel; Vandervoort Petra; Brepoels Kathleen; Collen Désiré; De Maeyer Marc
Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling.
Thrombosis and haemostasis 2002;87(4):666-73.
2002: Maquoi Erik; Munaut Carine; Colige Alain; Collen Désiré; Lijnen H Roger
Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity.
Diabetes 2002;51(4):1093-101.
2002: Lijnen H R; Van Hoef B; Frederix L; Rio M C; Collen D
Adipocyte hypertrophy in stromelysin-3 deficient mice with nutritionally induced obesity.
Thrombosis and haemostasis 2002;87(3):530-5.
2002: Luttun Aernout; Lupu Florea; Storkebaum Erik; Hoylaerts Marc F; Moons Lieve; Crawley James; Bono Françoise; Poole A Robin; Tipping Peter; Herbert Jean-Marc; Collen Désiré; Carmeliet Peter
Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(3):499-505.
2002: Lijnen H R; Maquoi E; Hansen L B; Van Hoef B; Frederix L; Collen D
Matrix metalloproteinase inhibition impairs adipose tissue development in mice.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(3):374-9.
2002: Baes M; Dewerchin M; Janssen A; Collen D; Carmeliet P
Generation of Pex5-loxP mice allowing the conditional elimination of peroxisomes.
Genesis (New York, N.Y. : 2000) 2002;32(2):177-8.
2002: Stalmans Ingeborg; Ng Yin-Shan; Rohan Richard; Fruttiger Marcus; Bouché Ann; Yuce Ali; Fujisawa Hajime; Hermans Bart; Shani Moshe; Jansen Sandra; Hicklin Dan; Anderson David J; Gardiner Tom; Hammes Hans-Peter; Moons Lieve; Dewerchin Mieke; Collen Désiré; Carmeliet Peter; D'Amore Patricia A
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms.
The Journal of clinical investigation 2002;109(3):327-36.
2002: Maes Christa; Carmeliet Peter; Moermans Karen; Stockmans Ingrid; Smets Nico; Collen Désiré; Bouillon Roger; Carmeliet Geert
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.
Mechanisms of development 2002;111(1-2):61-73.
2002: Warmerdam Petra A M; Vanderlick Kristel; Vandervoort Petra; De Smedt Heidi; Plaisance Stéphane; De Maeyer Marc; Collen Désiré
Staphylokinase-specific cell-mediated immunity in humans.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(1):155-61.
2002: VandenDriessche Thierry; Naldini Luigi; Collen Desire; Chuah Marinee K L
Oncoretroviral and lentiviral vector-mediated gene therapy.
Methods in enzymology 2002;346():573-89.
2001: Van Cromphaut S J; Dewerchin M; Hoenderop J G; Stockmans I; Van Herck E; Kato S; Bindels R J; Collen D; Carmeliet P; Bouillon R; Carmeliet G
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(23):13324-9.
2001: Ver Heyen M; Heymans S; Antoons G; Reed T; Periasamy M; Awede B; Lebacq J; Vangheluwe P; Dewerchin M; Collen D; Sipido K; Carmeliet P; Wuytack F
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.
Circulation research 2001;89(9):838-46.
2001: Vermeersch P; Nong Z; Stabile E; Varenne O; Gillijns H; Pellens M; Van Pelt N; Hoylaerts M; De Scheerder I; Collen D; Janssens S
L-arginine administration reduces neointima formation after stent injury in rats by a nitric oxide-mediated mechanism.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(10):1604-9.
2001: Brusselmans K; Bono F; Maxwell P; Dor Y; Dewerchin M; Collen D; Herbert J M; Carmeliet P
Hypoxia-inducible factor-2alpha (HIF-2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia.
The Journal of biological chemistry 2001;276(42):39192-6.
2001: VandenDriessche T; Collen D; Chuah M K
Viral vector-mediated gene therapy for hemophilia.
Current gene therapy 2001;1(3):301-15.
2001: Collen D
Revival of plasmin as a therapeutic agent?
Thrombosis and haemostasis 2001;86(3):731-2.
2001: Silence J; Lupu F; Collen D; Lijnen H R
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(9):1440-5.
2001: Nuyens D; Stengl M; Dugarmaa S; Rossenbacker T; Compernolle V; Rudy Y; Smits J F; Flameng W; Clancy C E; Moons L; Vos M A; Dewerchin M; Benndorf K; Collen D; Carmeliet E; Carmeliet P
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome.
Nature medicine 2001;7(9):1021-7.
2001: Dewerchin M; Collen D; Lijnen H R
Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
Thrombosis and haemostasis 2001;86(2):640-6.
2001: Melis E; Moons L; De Mol M; Herbert J M; Mackman N; Collen D; Carmeliet P; Dewerchin M
Targeted deletion of the cytosolic domain of tissue factor in mice does not affect development.
Biochemical and biophysical research communications 2001;286(3):580-6.
2001: Armstrong P W; Collen D
Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2.
Circulation 2001;103(24):2987-92.
2001: Lijnen H R; Van Hoef B; Collen D
Inactivation of the serpin alpha(2)-antiplasmin by stromelysin-1.
Biochimica et biophysica acta 2001;1547(2):206-13.
2001: Armstrong P W; Collen D
Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1.
Circulation 2001;103(23):2862-6.
2001: Moons L; Vanlinthout I; Roelants I; Moreadith R; Collen D; Rapold H J
Toxicology studies with recombinant staphylokinase and with SY 161-P5, a polyethylene glycol-derivatized cysteine-substitution mutant.
Toxicologic pathology 2001;29(3):285-91.
2001: Quarck R; De Geest B; Stengel D; Mertens A; Lox M; Theilmeier G; Michiels C; Raes M; Bult H; Collen D; Van Veldhoven P; Ninio E; Holvoet P
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
Circulation 2001;103(20):2495-500.
2001: Holvoet P; Mertens A; Verhamme P; Bogaerts K; Beyens G; Verhaeghe R; Collen D; Muls E; Van de Werf F
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(5):844-8.
2001: Nagai N; De Mol M; Van Hoef B; Verstreken M; Collen D
Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
Blood 2001;97(10):3086-92.
2001: Carmeliet P; Moons L; Luttun A; Vincenti V; Compernolle V; De Mol M; Wu Y; Bono F; Devy L; Beck H; Scholz D; Acker T; DiPalma T; Dewerchin M; Noel A; Stalmans I; Barra A; Blacher S; Vandendriessche T; Ponten A; Eriksson U; Plate K H; Foidart J M; Schaper W; Charnock-Jones D S; Hicklin D J; Herbert J M; Collen D; Persico M G
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
Nature medicine 2001;7(5):575-83.
2001: Ugwu F; Lemmens G; Collen D; Lijnen H R
Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity.
Thrombosis research 2001;102(1):61-9.
2001: Lijnen H R; Bloemmen F; Vereecken A; Collen D
Enzyme-linked immunosorbent assay for the specific detection of angiostatin-like plasminogen moieties in biological samples.
Thrombosis research 2001;102(1):53-9.
2001: Levi M; Moons L; Bouché A; Shapiro S D; Collen D; Carmeliet P
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
Circulation 2001;103(15):2014-20.
2001: Bajou K; Masson V; Gerard R D; Schmitt P M; Albert V; Praus M; Lund L R; Frandsen T L; Brunner N; Dano K; Fusenig N E; Weidle U; Carmeliet G; Loskutoff D; Collen D; Carmeliet P; Foidart J M; Noël A
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
The Journal of cell biology 2001;152(4):777-84.
2001: Beckers M; Gabriëls J; van der Maarel S; De Vriese A; Frants R R; Collen D; Belayew A
Active genes in junk DNA? Characterization of DUX genes embedded within 3.3 kb repeated elements.
Gene 2001;264(1):51-7.
2001: Angelillo-Scherrer A; de Frutos P; Aparicio C; Melis E; Savi P; Lupu F; Arnout J; Dewerchin M; Hoylaerts M; Herbert J; Collen D; Dahlbäck B; Carmeliet P
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.
Nature medicine 2001;7(2):215-21.
2001: Arza B; De Maeyer M; Félez J; Collen D; Lijnen H R
Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3).
European journal of biochemistry / FEBS 2001;268(3):826-31.
2001: Conway E M; Collen D; Carmeliet P
Molecular mechanisms of blood vessel growth.
Cardiovascular research 2001;49(3):507-21.
2001: De Geest B; Van Linthout S; Collen D
Sustained expression of human apo A-I following adenoviral gene transfer in mice.
Gene therapy 2001;8(2):121-7.
2001: Chuah M K; Collen D; VandenDriessche T
Gene therapy for hemophilia.
The journal of gene medicine 2001;3(1):3-20.
2001: Sinnaeve P; Chiche J D; Nong Z; Varenne O; Van Pelt N; Gillijns H; Collen D; Bloch K D; Janssens S
Soluble guanylate cyclase alpha(1) and beta(1) gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects.
Circulation research 2001;88(1):103-9.
2001: Collen D
Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2001;():1-9.
2000: Budts W; Pokreisz P; Nong Z; Van Pelt N; Gillijns H; Gerard R; Lyons R; Collen D; Bloch K D; Janssens S
Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.
Circulation 2000;102(23):2880-5.
2000: Lijnen H R; Arza B; Van Hoef B; Collen D; Declerck P J
Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3).
The Journal of biological chemistry 2000;275(48):37645-50.
2000: Arza B; Hoylaerts M F; Félez J; Collen D; Lijnen H R
Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator.
European journal of biochemistry / FEBS 2000;267(21):6378-84.
2000: De Geest B; Stengel D; Landeloos M; Lox M; Le Gat L; Collen D; Holvoet P; Ninio E
Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(10):E68-75.
2000: Theilmeier G; De Geest B; Van Veldhoven P P; Stengel D; Michiels C; Lox M; Landeloos M; Chapman M J; Ninio E; Collen D; Himpens B; Holvoet P
HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(13):2032-9.
2000: Collen D; Sinnaeve P; Demarsin E; Moreau H; De Maeyer M; Jespers L; Laroche Y; Van de Werf F
Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction.
Circulation 2000;102(15):1766-72.
2000: Laroche Y; Heymans S; Capaert S; De Cock F; Demarsin E; Collen D
Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes.
Blood 2000;96(4):1425-32.
2000: Lijnen H R; Collen D
Molecular basis of thrombolytic therapy.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2000;7(4):373-81.
2000: Arza B; Félez J; Fábregas P; Laroche Y; Collen D; Lijnen H R
Plasminogen binding properties of macrophage inflammatory protein (MIP)-2alpha.
Thrombosis and haemostasis 2000;84(1):71-7.
2000: Lijnen H R; Lupu F; Collen D; Le Naour F; Boucheix C
CD9 gene deficiency does not affect smooth muscle cell migration and neointima formation after vascular injury in mice.
Thrombosis and haemostasis 2000;83(6):956-61.
2000: Varenne O; Sinnaeve P; Gillijns H; Iung B; Laurysens V; Meurrens K; Bout B; Valerio D; Collen D; Janssens S P; Gerard R D
Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries.
Human gene therapy 2000;11(9):1329-39.
2000: Creemers E; Cleutjens J; Smits J; Heymans S; Moons L; Collen D; Daemen M; Carmeliet P
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction.
The American journal of pathology 2000;156(6):1865-73.
2000: Lijnen H R; Van Hoef B; Dewerchin M; Collen D
Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(6):1488-92.
2000: Carmeliet P; Collen D
Molecular basis of angiogenesis. Role of VEGF and VE-cadherin.
Annals of the New York Academy of Sciences 2000;902():249-62; discussion 262-4.
2000: Heymans S; Vanderschueren S; Verhaeghe R; Stockx L; Lacroix H; Nevelsteen A; Laroche Y; Collen D
Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion.
Thrombosis and haemostasis 2000;83(5):666-71.
2000: Armstrong P W; Burton J R; Palisaitis D; Thompson C R; Van de Werf F; Rose B; Collen D; Teo K K
Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS).
American heart journal 2000;139(5):820-3.
2000: Baes M; Huyghe S; Carmeliet P; Declercq P E; Collen D; Mannaerts G P; Van Veldhoven P P
Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids.
The Journal of biological chemistry 2000;275(21):16329-36.
2000: Chuah M K; Van Damme A; Zwinnen H; Goovaerts I; Vanslembrouck V; Collen D; Vandendriessche T
Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice.
Human gene therapy 2000;11(5):729-38.
2000: Holvoet P; Van Cleemput J; Collen D; Vanhaecke J
Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(3):698-702.
2000: Dewerchin M; Liang Z; Moons L; Carmeliet P; Castellino F J; Collen D; Rosen E D
Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice.
Thrombosis and haemostasis 2000;83(2):185-90.
2000: Carmeliet P; Collen D
Transgenic mouse models in angiogenesis and cardiovascular disease.
The Journal of pathology 2000;190(3):387-405.
2000: Holvoet P; De Geest B; Van Linthout S; Lox M; Danloy S; Raes K; Collen D
The Arg123-Tyr166 central domain of human ApoAI is critical for lecithin:cholesterol acyltransferase-induced hyperalphalipoproteinemia and HDL remodeling in transgenic mice.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(2):459-66.
2000: Conway E M; Pollefeyt S; Cornelissen J; DeBaere I; Steiner-Mosonyi M; Ong K; Baens M; Collen D; Schuh A C
Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions.
Blood 2000;95(4):1435-42.
2000: Vanwetswinkel S; Plaisance S; Zhi-Yong Z; Vanlinthout I; Brepoels K; Lasters I; Collen D; Jespers L
Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase.
Blood 2000;95(3):936-42.
2000: De Geest B; Van Linthout S; Lox M; Collen D; Holvoet P
Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer.
Human gene therapy 2000;11(1):101-12.
2000: Lijnen H R; Van Hoef B; Ugwu F; Collen D; Roelants I
Specific proteolysis of human plasminogen by a 24 kDa endopeptidase from a novel Chryseobacterium Sp.
Biochemistry 2000;39(2):479-88.
1999: Sinnaeve P; Varenne O; Collen D; Janssens S
Gene therapy in the cardiovascular system: an update.
Cardiovascular research 1999;44(3):498-506.
1999: Nagai N; Vanlinthout I; Collen D
Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
Circulation 1999;100(25):2541-6.
1999: Lijnen H R; Van Hoef B; Vanlinthout I; Verstreken M; Rio M C; Collen D
Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(12):2863-70.
1999: Lijnen H R; Soloway P; Collen D
Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice.
Circulation research 1999;85(12):1186-91.
1999: Merchiers P; Bulens F; Stockmans I; De Vriese A; Convents R; Bouillon R; Collen D; Belayew A; Carmeliet G
1,25-Dihydroxyvitamin D(3) induction of the tissue-type plasminogen activator gene is mediated through its multihormone-responsive enhancer.
FEBS letters 1999;460(2):289-96.
1999: Theilmeier G; Lenaerts T; Remacle C; Collen D; Vermylen J; Hoylaerts M F
Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress.
Blood 1999;94(8):2725-34.
1999: Heymans S; Luttun A; Nuyens D; Theilmeier G; Creemers E; Moons L; Dyspersin G D; Cleutjens J P; Shipley M; Angellilo A; Levi M; Nübe O; Baker A; Keshet E; Lupu F; Herbert J M; Smits J F; Shapiro S D; Baes M; Borgers M; Collen D; Daemen M J; Carmeliet P
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Nature medicine 1999;5(10):1135-42.
1999: Ugwu F; Lemmens G; Collen D; Lijnen H R
Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3).
Thrombosis and haemostasis 1999;82(3):1127-31.
1999: Lijnen H R; Collen D
Matrix metalloproteinase system deficiencies and matrix degradation.
Thrombosis and haemostasis 1999;82(2):837-45.
1999: Collen D
The plasminogen (fibrinolytic) system.
Thrombosis and haemostasis 1999;82(2):259-70.
1999: VandenDriessche T; Vanslembrouck V; Goovaerts I; Zwinnen H; Vanderhaeghen M L; Collen D; Chuah M K
Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(18):10379-84.
1999: Gabriëls J; Beckers M C; Ding H; De Vriese A; Plaisance S; van der Maarel S M; Padberg G W; Frants R R; Hewitt J E; Collen D; Belayew A
Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element.
Gene 1999;236(1):25-32.
1999: Merchiers P; Bulens F; De Vriese A; Collen D; Belayew A
Involvement of Sp1 in basal and retinoic acid induced transcription of the human tissue-type plasminogen activator gene.
FEBS letters 1999;456(1):149-54.
1999: Carmeliet P; Lampugnani M G; Moons L; Breviario F; Compernolle V; Bono F; Balconi G; Spagnuolo R; Oosthuyse B; Dewerchin M; Zanetti A; Angellilo A; Mattot V; Nuyens D; Lutgens E; Clotman F; de Ruiter M C; Gittenberger-de Groot A; Poelmann R; Lupu F; Herbert J M; Collen D; Dejana E
Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis.
Cell 1999;98(2):147-57.
1999: Ding H; Benotmane A M; Suske G; Collen D; Belayew A
Functional interactions between Sp1 or Sp3 and the helicase-like transcription factor mediate basal expression from the human plasminogen activator inhibitor-1 gene.
The Journal of biological chemistry 1999;274(28):19573-80.
1999: Jespers L; Lijnen H R; Vanwetswinkel S; Van Hoef B; Brepoels K; Collen D; De Maeyer M
Guiding a docking mode by phage display: selection of correlated mutations at the staphylokinase-plasmin interface.
Journal of molecular biology 1999;290(2):471-9.
1999: Rabhi-Sabile S; Steiner-Mosonyi M; Pollefeyt S; Collen D; Pouvelle B; Gysin J; Boffa M C; Conway E M
Plasmodium falciparum-infected erythrocytes: a mutational analysis of cytoadherence via murine thrombomodulin.
Thrombosis and haemostasis 1999;81(5):815-21.
1999: Lijnen H R; Lupu F; Moons L; Carmeliet P; Goulding D; Collen D
Temporal and topographic matrix metalloproteinase expression after vascular injury in mice.
Thrombosis and haemostasis 1999;81(5):799-807.
1999: Varenne O; Gerard R D; Sinnaeve P; Gillijns H; Collen D; Janssens S
Percutaneous adenoviral gene transfer into porcine coronary arteries: is catheter-based gene delivery adapted to coronary circulation?
Human gene therapy 1999;10(7):1105-15.
1999: Holvoet P; Collen D; Van de Werf F
Malondialdehyde-modified LDL as a marker of acute coronary syndromes.
JAMA : the journal of the American Medical Association 1999;281(18):1718-21.
1999: Nagai N; De Mol M; Lijnen H R; Carmeliet P; Collen D
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.
Circulation 1999;99(18):2440-4.
1999: Conway E M; Pollefeyt S; Cornelissen J; DeBaere I; Steiner-Mosonyi M; Weitz J I; Weiler-Guettler H; Carmeliet P; Collen D
Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development.
Blood 1999;93(10):3442-50.
1999: Carmeliet P; Ng Y S; Nuyens D; Theilmeier G; Brusselmans K; Cornelissen I; Ehler E; Kakkar V V; Stalmans I; Mattot V; Perriard J C; Dewerchin M; Flameng W; Nagy A; Lupu F; Moons L; Collen D; D'Amore P A; Shima D T
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.
Nature medicine 1999;5(5):495-502.
1999: Jespers L; Vanwetswinkel S; Lijnen H R; Van Herzeele N; Van Hoef B; Demarsin E; Collen D; De Maeyer M
Structural and functional basis of plasminogen activation by staphylokinase.
Thrombosis and haemostasis 1999;81(4):479-85.
1999: Lijnen H R; Okada K; Matsuo O; Collen D; Dewerchin M
Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding.
Blood 1999;93(7):2274-81.
1999: Praus M; Wauterickx K; Collen D; Gerard R D
Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors.
Gene therapy 1999;6(2):227-36.
1999: Chan J C; Carmeliet P; Moons L; Rosen E D; Huang Z F; Broze G J; Collen D; Castellino F J
Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit.
The Journal of clinical investigation 1999;103(4):475-82.
1999: Carmeliet P; Collen D
Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development.
Current topics in microbiology and immunology 1999;237():133-58.
1998: Moons L; Shi C; Ploplis V; Plow E; Haber E; Collen D; Carmeliet P
Reduced transplant arteriosclerosis in plasminogen-deficient mice.
The Journal of clinical investigation 1998;102(10):1788-97.
1998: Jalbert L R; Rosen E D; Moons L; Chan J C; Carmeliet P; Collen D; Castellino F J
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.
The Journal of clinical investigation 1998;102(8):1481-8.
1998: Holvoet P; Vanhaecke J; Janssens S; Van de Werf F; Collen D
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.
Circulation 1998;98(15):1487-94.
1998: Ding H; Beckers M C; Plaisance S; Marynen P; Collen D; Belayew A
Characterization of a double homeodomain protein (DUX1) encoded by a cDNA homologous to 3.3 kb dispersed repeated elements.
Human molecular genetics 1998;7(11):1681-94.
1998: Chuah M K; Collen D; VandenDriessche T
Gene therapy for hemophilia: hopes and hurdles.
Critical reviews in oncology/hematology 1998;28(3):153-71.
1998: Carmeliet P; Collen D
Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system.
Thrombosis research 1998;91(6):255-85.
1998: Jenné S; Brepoels K; Collen D; Jespers L
High resolution mapping of the B cell epitopes of staphylokinase in humans using negative selection of a phage-displayed antigen library.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(6):3161-8.
1998: Varenne O; Pislaru S; Gillijns H; Van Pelt N; Gerard R D; Zoldhelyi P; Van de Werf F; Collen D; Janssens S P
Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs.
Circulation 1998;98(9):919-26.
1998: Bajou K; Noël A; Gerard R D; Masson V; Brunner N; Holst-Hansen C; Skobe M; Fusenig N E; Carmeliet P; Collen D; Foidart J M
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Nature medicine 1998;4(8):923-8.
1998: Carmeliet P; Moons L; Collen D
Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis.
Cardiovascular research 1998;39(1):8-33.
1998: Carmeliet P; Dor Y; Herbert J M; Fukumura D; Brusselmans K; Dewerchin M; Neeman M; Bono F; Abramovitch R; Maxwell P; Koch C J; Ratcliffe P; Moons L; Jain R K; Collen D; Keshert E;
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
Nature 1998;394(6692):485-90.
1998: Liang Z; Cooper A; DeFord M E; Carmeliet P; Collen D; Castellino F J; Rosen E D
Cloning and characterization of a cDNA encoding murine coagulation factor X.
Thrombosis and haemostasis 1998;80(1):87-91.
1998: Lijnen H R; Van Hoef B; Lupu F; Moons L; Carmeliet P; Collen D
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(7):1035-45.
1998: Holvoet P; Danloy S; Deridder E; Lox M; Bernar H; Dhoest A; Collen D
Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
The Journal of clinical investigation 1998;102(2):379-85.
1998: Carmeliet P; Collen D
Tissue factor.
The international journal of biochemistry & cell biology 1998;30(6):661-7.
1998: Lijnen H R; Silence J; Lemmens G; Frederix L; Collen D
Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.
Thrombosis and haemostasis 1998;79(6):1171-6.
1998: Carmeliet P; Collen D
Vascular development and disorders: molecular analysis and pathogenic insights.
Kidney international 1998;53(6):1519-49.
1998: Ugwu F; Van Hoef B; Bini A; Collen D; Lijnen H R
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).
Biochemistry 1998;37(20):7231-6.
1998: Jespers L; Van Herzeele N; Lijnen H R; Van Hoef B; De Maeyer M; Collen D; Lasters I
Arginine 719 in human plasminogen mediates formation of the staphylokinase:plasmin activator complex.
Biochemistry 1998;37(18):6380-6.
1998: Janssens S; Flaherty D; Nong Z; Varenne O; van Pelt N; Haustermans C; Zoldhelyi P; Gerard R; Collen D
Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats.
Circulation 1998;97(13):1274-81.
1998: Lijnen H R; Ugwu F; Bini A; Collen D
Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3).
Biochemistry 1998;37(14):4699-702.
1998: Heymans S; Verhaeghe R; Stockx L; Collen D
Feasibility study of catheter-directed thrombolysis with recombinant staphylokinase in deep venous thrombosis.
Thrombosis and haemostasis 1998;79(3):517-9.
1998: Holvoet P; Theilmeier G; Shivalkar B; Flameng W; Collen D
LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(3):415-22.
1998: Collen D
Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent.
Nature medicine 1998;4(3):279-84.
1998: Lijnen H R; Silence J; Van Hoef B; Collen D
Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice.
Blood 1998;91(6):2045-53.
1998: Chuah M K; Brems H; Vanslembrouck V; Collen D; Vandendriessche T
Bone marrow stromal cells as targets for gene therapy of hemophilia A.
Human gene therapy 1998;9(3):353-65.
1998: Jalbert L R; Rosen E D; Lissens A; Carmeliet P; Collen D; Castellino F J
Nucleotide structure and characterization of the murine gene encoding anticoagulant protein C.
Thrombosis and haemostasis 1998;79(2):310-6.
1998: Holvoet P; Stassen J M; Van Cleemput J; Collen D; Vanhaecke J
Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(1):100-7.
1998: Carmeliet P; Moons L; Dewerchin M; Rosenberg S; Herbert J M; Lupu F; Collen D
Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.
The Journal of cell biology 1998;140(1):233-45.
1997: De Geest B; Zhao Z; Collen D; Holvoet P
Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice.
Circulation 1997;96(12):4349-56.
1997: Carmeliet P; Moons L; Lijnen R; Baes M; Lemaître V; Tipping P; Drew A; Eeckhout Y; Shapiro S; Lupu F; Collen D
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.
Nature genetics 1997;17(4):439-44.
1997: Holvoet P; Collen D
beta-VLDL hypercholesterolemia relative to LDL hypercholesterolemia is associated with higher levels of oxidized lipoproteins and a more rapid progression of coronary atherosclerosis in rabbits.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):2376-82.
1997: Carmeliet P; Moons L; Lijnen R; Janssens S; Lupu F; Collen D; Gerard R D
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice.
Circulation 1997;96(9):3180-91.
1997: Rosen E D; Chan J C; Idusogie E; Clotman F; Vlasuk G; Luther T; Jalbert L R; Albrecht S; Zhong L; Lissens A; Schoonjans L; Moons L; Collen D; Castellino F J; Carmeliet P
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding.
Nature 1997;390(6657):290-4.
1997: Carmeliet P; Collen D
Molecular analysis of blood vessel formation and disease.
The American journal of physiology 1997;273(5 Pt 2):H2091-104.
1997: Nong Z; Hoylaerts M; Van Pelt N; Collen D; Janssens S
Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats.
Circulation research 1997;81(5):865-9.
1997: Carmeliet P; Moons L; Herbert J M; Crawley J; Lupu F; Lijnen R; Collen D
Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice.
Circulation research 1997;81(5):829-39.
1997: Holvoet P; Collen D
Thrombosis and atherosclerosis.
Current opinion in lipidology 1997;8(5):320-8.
1997: Gerard R D; Collen D
Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis.
Cardiovascular research 1997;35(3):451-8.
1997: Okada K; Lijnen H R; Dewerchin M; Belayew A; Matsuo O; Collen D; Bernaerts R
Characterization and targeting of the murine alpha2-antiplasmin gene.
Thrombosis and haemostasis 1997;78(3):1104-10.
1997: Vanderschueren S; Van Vlaenderen I; Collen D
Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model.
Stroke; a journal of cerebral circulation 1997;28(9):1783-8.
1997: Baes M; Gressens P; Baumgart E; Carmeliet P; Casteels M; Fransen M; Evrard P; Fahimi D; Declercq P E; Collen D; van Veldhoven P P; Mannaerts G P
A mouse model for Zellweger syndrome.
Nature genetics 1997;17(1):49-57.
1997: Rolling F; Nong Z; Pisvin S; Collen D
Adeno-associated virus-mediated gene transfer into rat carotid arteries.
Gene therapy 1997;4(8):757-61.
1997: Vanderschueren S; Dens J; Kerdsinchai P; Desmet W; Vrolix M; De Man F; Van den Heuvel P; Hermans L; Collen D; Van de Werf F
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction.
American heart journal 1997;134(2 Pt 1):213-9.
1997: Carmeliet P; Stassen J M; Van Vlaenderen I; Meidell R S; Collen D; Gerard R D
Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice.
Blood 1997;90(4):1527-34.
1997: Benotmane A M; Hoylaerts M F; Collen D; Belayew A
Nonisotopic quantitative analysis of protein-DNA interactions at equilibrium.
Analytical biochemistry 1997;250(2):181-5.
1997: Collen D
Thrombolytic therapy.
Thrombosis and haemostasis 1997;78(1):742-6.
1997: Jespers L; Jenné S; Lasters I; Collen D
Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage.
Journal of molecular biology 1997;269(5):704-18.
1997: Dhoest A; Zhao Z; De Geest B; Deridder E; Sillen A; Engelborghs Y; Collen D; Holvoet P
Role of the Arg123-Tyr166 paired helix of apolipoprotein A-I in lecithin:cholesterol acyltransferase activation.
The Journal of biological chemistry 1997;272(25):15967-72.
1997: Lijnen H R; Lasters I; Verstreken M; Collen D; Jespers L
Screening panels of monoclonal antibodies using phage-displayed antigen.
Analytical biochemistry 1997;248(2):211-5.
1997: Holvoet P; Danloy S; Collen D
Role of the carboxy-terminal domain of human apolipoprotein AI in high-density-lipoprotein metabolism--a study based on deletion and substitution variants in transgenic mice.
European journal of biochemistry / FEBS 1997;245(3):642-7.
1997: Carmeliet P; Moons L; Dewerchin M; Mackman N; Luther T; Breier G; Ploplis V; Müller M; Nagy A; Plow E; Gerard R; Edgington T; Risau W; Collen D
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Annals of the New York Academy of Sciences 1997;811():191-206.
1997: Carmeliet P; Collen D
Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis.
Current opinion in lipidology 1997;8(2):118-25.
1997: Lasters I; Van Herzeele N; Lijnen H R; Collen D; Jespers L
Enzymatic properties of phage-displayed fragments of human plasminogen.
European journal of biochemistry / FEBS 1997;244(3):946-52.
1997: Lijnen H R; Wagner E F; Collen D
Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
Thrombosis and haemostasis 1997;77(2):362-7.
1997: Carmeliet P; Moons L; Stassen J M; De Mol M; Bouché A; van den Oord J J; Kockx M; Collen D
Vascular wound healing and neointima formation induced by perivascular electric injury in mice.
The American journal of pathology 1997;150(2):761-76.
1997: Collen D; Stockx L; Lacroix H; Suy R; Vanderschueren S
Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency.
Circulation 1997;95(2):463-72.
1997: Collen D; De Cock F; Demarsin E; Jenné S; Lasters I; Laroche Y; Warmerdam P; Jespers L
Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns.
Circulation 1997;95(2):455-62.
1997: Carmeliet P; Moons L; Ploplis V; Plow E; Collen D
Impaired arterial neointima formation in mice with disruption of the plasminogen gene.
The Journal of clinical investigation 1997;99(2):200-8.
1997: Conway E M; Pollefeyt S; Collen D; Steiner-Mosonyi M
The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis.
Blood 1997;89(2):652-61.
1997: Bulens F; Merchiers P; Ibañez-Tallon I; De Vriese A; Nelles L; Claessens F; Belayew A; Collen D
Identification of a multihormone responsive enhancer far upstream from the human tissue-type plasminogen activator gene.
The Journal of biological chemistry 1997;272(1):663-71.
1996: Idusogie E; Rosen E D; Carmeliet P; Collen D; Castellino F J
Nucleotide structure and characterization of the murine blood coagulation factor VII gene.
Thrombosis and haemostasis 1996;76(6):957-64.
1996: Okada K; Lijnen H R; Moreau H; Vanderschueren S; Collen D
Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Thrombosis and haemostasis 1996;76(6):857-9.
1996: Schoonjans L; Albright G M; Li J L; Collen D; Moreadith R W
Pluripotential rabbit embryonic stem (ES) cells are capable of forming overt coat color chimeras following injection into blastocysts.
Molecular reproduction and development 1996;45(4):439-43.
1996: Gase A; Hartmann M; Gührs K H; Röcker A; Collen D; Behnke D; Schlott B
Functional significance of NH2- and COOH-terminal regions of staphylokinase in plasminogen activation.
Thrombosis and haemostasis 1996;76(5):755-60.
1996: Holvoet P; Donck J; Landeloos M; Brouwers E; Luijtens K; Arnout J; Lesaffre E; Vanrenterghem Y; Collen D
Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.
Thrombosis and haemostasis 1996;76(5):663-9.
1996: Lijnen H R; Van Hoef B; Collen D
Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.
European journal of biochemistry / FEBS 1996;241(3):840-8.
1996: Collen D; Vanderschueren S; Van de Werf F
Fibrin-selective thrombolytic therapy with recombinant staphylokinase.
Haemostasis 1996;26 Suppl 4():294-300.
1996: Carmeliet P; Collen D
Genetic analysis of the plasminogen and coagulation system in mice.
Haemostasis 1996;26 Suppl 4():132-53.
1996: Vanderschueren S; Collen D; van de Werf F
A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.
Thrombosis and haemostasis 1996;76(4):541-4.
1996: Nong Z; Stassen J M; Moons L; Collen D; Janssens S
Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.
Circulation 1996;94(8):1941-7.
1996: Carmeliet P; Mackman N; Moons L; Luther T; Gressens P; Van Vlaenderen I; Demunck H; Kasper M; Breier G; Evrard P; Müller M; Risau W; Edgington T; Collen D
Role of tissue factor in embryonic blood vessel development.
Nature 1996;383(6595):73-5.
1996: Huang Y Y; Bach M E; Lipp H P; Zhuo M; Wolfer D P; Hawkins R D; Schoonjans L; Kandel E R; Godfraind J M; Mulligan R; Collen D; Carmeliet P
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(16):8699-704.
1996: Lijnen H R; Carmeliet P; Bouché A; Moons L; Ploplis V A; Plow E F; Collen D
Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen.
Blood 1996;88(3):870-6.
1996: Holvoet P; Zhao Z; Deridder E; Dhoest A; Collen D
Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association.
The Journal of biological chemistry 1996;271(32):19395-401.
1996: Janssens S P; Bloch K D; Nong Z; Gerard R D; Zoldhelyi P; Collen D
Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats.
The Journal of clinical investigation 1996;98(2):317-24.
1996: Collen D; Moreau H; Stockx L; Vanderschueren S
Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction.
Circulation 1996;94(2):207-16.
1996: Collen D; Bernaerts R; Declerck P; De Cock F; Demarsin E; Jenné S; Laroche Y; Lijnen H R; Silence K; Verstreken M
Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization.
Circulation 1996;94(2):197-206.
1996: Vanderschueren S; Stassen J M; Collen D
Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model.
Journal of cardiovascular pharmacology 1996;27(6):809-15.
1996: Ding H; Descheemaeker K; Marynen P; Nelles L; Carvalho T; Carmo-Fonseca M; Collen D; Belayew A
Characterization of a helicase-like transcription factor involved in the expression of the human plasminogen activator inhibitor-1 gene.
DNA and cell biology 1996;15(6):429-42.
1996: Vanderschueren S; Collen D
Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
Thrombosis and haemostasis 1996;75(5):816-9.
1996: Carmeliet P; Ferreira V; Breier G; Pollefeyt S; Kieckens L; Gertsenstein M; Fahrig M; Vandenhoeck A; Harpal K; Eberhardt C; Declercq C; Pawling J; Moons L; Collen D; Risau W; Nagy A
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.
Nature 1996;380(6573):435-9.
1996: Idusogie E; Rosen E; Geng J P; Carmeliet P; Collen D; Castellino F J
Characterization of a cDNA encoding murine coagulation factor VII.
Thrombosis and haemostasis 1996;75(3):481-7.
1996: Collen D
Fibrin-selective thrombolytic therapy for acute myocardial infarction.
Circulation 1996;93(5):857-65.
1996: Dewerchin M; Nuffelen A V; Wallays G; Bouché A; Moons L; Carmeliet P; Mulligan R C; Collen D
Generation and characterization of urokinase receptor-deficient mice.
The Journal of clinical investigation 1996;97(3):870-8.
1996: Carmeliet P; Collen D
Gene manipulation and transfer of the plasminogen and coagulation system in mice.
Seminars in thrombosis and hemostasis 1996;22(6):525-42.
1995: Declerck P J; Verstreken M; Collen D
Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Thrombosis and haemostasis 1995;74(5):1305-9.
1995: Lijnen H R; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens G J
Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
European journal of biochemistry / FEBS 1995;234(1):350-7.
1995: Silence K; Hartmann M; Gührs K H; Gase A; Schlott B; Collen D; Lijnen H R
Structure-function relationships in staphylokinase as revealed by "clustered charge to alanine" mutagenesis.
The Journal of biological chemistry 1995;270(45):27192-8.
1995: Ploplis V A; Carmeliet P; Vazirzadeh S; Van Vlaenderen I; Moons L; Plow E F; Collen D
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.
Circulation 1995;92(9):2585-93.
1995: Lijnen H R; Moons L; Beelen V; Carmelie P; Collen D
Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Thrombosis and haemostasis 1995;74(4):1126-31.
1995: Vanderschueren S; Stockx L; Wilms G; Lacroix H; Verhaeghe R; Vermylen J; Collen D
Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase.
Circulation 1995;92(8):2050-7.
1995: Vanderschueren S; Barrios L; Kerdsinchai P; Van den Heuvel P; Hermans L; Vrolix M; De Man F; Benit E; Muyldermans L; Collen D
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
Circulation 1995;92(8):2044-9.
1995: Carmeliet P; Collen D
Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system.
Thrombosis and haemostasis 1995;74(1):429-36.
1995: Lijnen H R; Collen D
Fibrinolytic agents: mechanisms of activity and pharmacology.
Thrombosis and haemostasis 1995;74(1):387-90.
1995: Collen D; Lijnen H R
Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Thrombosis and haemostasis 1995;74(1):167-71.
1995: Verstraete M; Lijnen H R; Collen D
Thrombolytic agents in development.
Drugs 1995;50(1):29-42.
1995: Holvoet P; Perez G; Zhao Z; Brouwers E; Bernar H; Collen D
Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.
The Journal of clinical investigation 1995;95(6):2611-9.
1995: Collen D; Lijnen H R
New thrombolytic agents and strategies.
Baillière's clinical haematology 1995;8(2):425-35.
1995: Lijnen H R; Collen D
Mechanisms of physiological fibrinolysis.
Baillière's clinical haematology 1995;8(2):277-90.
1995: Lijnen H R; Stassen J M; Collen D
Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
Thrombosis and haemostasis 1995;73(5):845-9.
1995: Rodríguez P; Fuentes P; Barro M; Alvarez J G; Muñoz E; Collen D; Lijnen H R
Structural domains of streptokinase involved in the interaction with plasminogen.
European journal of biochemistry / FEBS 1995;229(1):83-90.
1995: Declerck P J; Carmeliet P; Verstreken M; De Cock F; Collen D
Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice.
The Journal of biological chemistry 1995;270(15):8397-400.
1995: Jun L; Arnout J; Vanhove P; Dol F; Lormeau J C; Herbert J M; Collen D; Van de Werf F
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Coronary artery disease 1995;6(3):257-63.
1995: Bulens F; Ibañez-Tallon I; Van Acker P; De Vriese A; Nelles L; Belayew A; Collen D
Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at -7 kilobases.
The Journal of biological chemistry 1995;270(13):7167-75.
1995: Lijnen H R; Van Hoef B; Collen D
Interactions of staphylokinase with human platelets.
Thrombosis and haemostasis 1995;73(3):472-7.
1995: Carmeliet P; Bouché A; De Clercq C; Janssen S; Pollefeyt S; Wyns S; Mulligan R C; Collen D
Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice.
Annals of the New York Academy of Sciences 1995;748():367-81; discussion 381-2.
1995: Collen D; Lijnen H R; Vanderschueren S
Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 1995;57(3):183-96; discussion 196-8.
1994: Carmeliet P; Mulligan R C; Collen D
Transgenic animals as tools for the study of fibrinolysis in vivo.
Journal of internal medicine 1994;236(4):455-9.
1994: Collen D; De Bono D P; Lijnen H R; Pannekoek H
Development of novel thrombolytic agents.
Journal of internal medicine 1994;236(4):433-7.
1994: Lijnen H R; Bachmann F; Collen D; Ellis V; Pannekoek H; Rijken D C; Thorsen S
Mechanisms of plasminogen activation.
Journal of internal medicine 1994;236(4):415-24.
1994: Lijnen H R; De Cock F; Collen D
Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
European journal of biochemistry / FEBS 1994;224(2):567-74.
1994: Lijnen H R; van Hoef B; Beelen V; Collen D
Characterization of the murine plasma fibrinolytic system.
European journal of biochemistry / FEBS 1994;224(3):863-71.
1994: Lijnen H R; De Cock F; Van Hoef B; Schlott B; Collen D
Characterization of the interaction between plasminogen and staphylokinase.
European journal of biochemistry / FEBS 1994;224(1):143-9.
1994: Vanderschueren S M; Stassen J M; Collen D
On the immunogenicity of recombinant staphylokinase in patients and in animal models.
Thrombosis and haemostasis 1994;72(2):297-301.
1994: Collen D; Lijnen H R
Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?
Blood 1994;84(3):680-6.
1994: Audenaert A M; Knockaert I; Collen D; Declerck P J
Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
The Journal of biological chemistry 1994;269(30):19559-64.
1994: Collen D; Stassen J M; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero J L; Lijnen H R; Gold H K
Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Thrombosis and haemostasis 1994;72(1):98-104.
1994: Collen D
Is there an optimal thrombolytic regimen?
Coronary artery disease 1994;5(4):287-91.
1994: Carmeliet P; Schoonjans L; Kieckens L; Ream B; Degen J; Bronson R; De Vos R; van den Oord J J; Collen D; Mulligan R C
Physiological consequences of loss of plasminogen activator gene function in mice.
Nature 1994;368(6470):419-24.
1994: Kiss R G; Stassen J M; Deckmyn H; Roskams T; Gold H K; Plow E F; Collen D
Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(3):375-80.
1994: Kiss R G; Lu H R; Roskams T; Jang I K; Plow E F; Gold H K; Collen D
Time course of the effects of a single bolus injection of F(ab')2 fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation, and bleeding time in dogs.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(3):367-74.
1994: Schlott B; Hartmann M; Gührs K H; Birch-Hirschfeld E; Gase A; Vettermann S; Collen D; Lijnen H R
Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26.
Biochimica et biophysica acta 1994;1204(2):235-42.
1994: Garabedian H D; Gold H K; Newell J B; Collen D; Hagstrom J N; Bovill E G
Accelerated thrombin generation during anticoagulation in patients with unstable angina pectoris.
Blood 1994;83(4):1155.
1994: Schlott B; Hartmann M; Gührs K H; Birch-Hirschfeid E; Pohl H D; Vanderschueren S; Van de Werf F; Michoel A; Collen D; Behnke D
High yield production and purification of recombinant staphylokinase for thrombolytic therapy.
Bio/technology (Nature Publishing Company) 1994;12(2):185-9.
1994: Holvoet P; Perez G; Bernar H; Brouwers E; Vanloo B; Rosseneu M; Collen D
Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation.
The Journal of clinical investigation 1994;93(1):89-98.
1994: Collen D; Lu H R; Stassen J M; Vreys I; Yasuda T; Bunting S; Gold H K
Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis.
Thrombosis and haemostasis 1994;71(1):95-102.
1994: Ueshima S; Holvoet P; Lijnen H R; Nelles L; Seghers V; Collen D
Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator.
Thrombosis and haemostasis 1994;71(1):134-40.
1994: Declerck P J; Vanderschueren S; Billiet J; Moreau H; Collen D
Prevalence and induction of circulating antibodies against recombinant staphylokinase.
Thrombosis and haemostasis 1994;71(1):129-33.
1993: Collen D; Lijnen H R
On the future of thrombolytic therapy for acute myocardial infarction.
The American journal of cardiology 1993;72(19):46G-50G.
1993: Carmeliet P; Stassen J M; Schoonjans L; Ream B; van den Oord J J; De Mol M; Mulligan R C; Collen D
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.
The Journal of clinical investigation 1993;92(6):2756-60.
1993: Carmeliet P; Kieckens L; Schoonjans L; Ream B; van Nuffelen A; Prendergast G; Cole M; Bronson R; Collen D; Mulligan R C
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.
The Journal of clinical investigation 1993;92(6):2746-55.
1993: Kohmura C; Gold H K; Yasuda T; Holt R; Nedelman M A; Guerrero J L; Weisman H F; Collen D
A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1993;13(12):1837-42.
1993: Van de Werf F; Lijnen H R; Collen D
Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
Coronary artery disease 1993;4(10):929-33.
1993: Ueshima S; Silence K; Collen D; Lijnen H R
Molecular conversions of recombinant staphylokinase during plasminogen activation in purified systems and in human plasma.
Thrombosis and haemostasis 1993;70(3):495-9.
1993: Lijnen H R; Beelen V; Declerck P J; Collen D
Bio-immunoassay for staphylokinase in blood.
Thrombosis and haemostasis 1993;70(3):491-4.
1993: Van de Werf F; Janssens L; Brzostek T; Mortelmans L; Wackers F J; Willems G M; Heidbüchel H; Lesaffre E; Scheys I; Collen D
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.
Journal of the American College of Cardiology 1993;22(2):407-16.
1993: Lijnen H R; Van Hoef B; Smith R A; Collen D
Functional properties of p-anisoylated plasmin-staphylokinase complex.
Thrombosis and haemostasis 1993;70(2):326-31.
1993: Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs K H; Lijnen H R
Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
European journal of biochemistry / FEBS 1993;216(1):307-14.
1993: Silence K; Collen D; Lijnen H R
Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.
Blood 1993;82(4):1175-83.
1993: Collen D
Towards improved thrombolytic therapy.
Lancet 1993;342(8862):34-6.
1993: Collen D; Van de Werf F
Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.
Circulation 1993;87(6):1850-3.
1993: Yasuda T; Gold H K; Kohmura C; Guerrero L; Yaoita H; Fallon J T; Bunting S; Collen D
Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1993;13(5):738-47.
1993: Stassen J M; Rapold H J; Vanlinthout I; Collen D
Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs.
Thrombosis and haemostasis 1993;69(5):454-9.
1993: Silence K; Collen D; Lijnen H R
Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin.
The Journal of biological chemistry 1993;268(13):9811-6.
1993: Collen D; Schlott B; Engelborghs Y; Van Hoef B; Hartmann M; Lijnen H R; Behnke D
On the mechanism of the activation of human plasminogen by recombinant staphylokinase.
The Journal of biological chemistry 1993;268(11):8284-9.
1993: Collen D; De Cock F; Stassen J M
Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Circulation 1993;87(3):996-1006.
1993: Holvoet P; Dewerchin M; Stassen J M; Lijnen H R; Tollenaere T; Gaffney P J; Collen D
Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Circulation 1993;87(3):1007-16.
1993: Holvoet P; Laroche Y; Stassen J M; Lijnen H R; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
Blood 1993;81(3):696-703.
1993: Lijnen H R; Van Hoef B; Collen D
Interaction of staphylokinase with different molecular forms of plasminogen.
European journal of biochemistry / FEBS 1993;211(1-2):91-7.
1993: Lijnen H R; Collen D
Molecular interactions between tissue-type plasminogen activator and plasminogen.
Methods in enzymology 1993;223():197-206.
1992: Holvoet P; Laroche Y; Lijnen H R; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
European journal of biochemistry / FEBS 1992;210(3):945-52.
1992: Lijnen H R; Collen D
Remaining perspectives of mutant and chimeric plasminogen activators.
Annals of the New York Academy of Sciences 1992;667():357-64.
1992: Collen D; Lijnen H R
Fibrin-specific fibrinolysis.
Annals of the New York Academy of Sciences 1992;667():259-71.
1992: Imura Y; Stassen J M; Bunting S; Stockmans F; Collen D
Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.
Blood 1992;80(5):1247-53.
1992: Arnout J; Simoons M; de Bono D; Rapold H J; Collen D; Verstraete M
Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Journal of the American College of Cardiology 1992;20(3):513-9.
1992: Imura Y; Stassen J M; Vreys I; Lesaffre E; Gold H K; Collen D
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Thrombosis and haemostasis 1992;68(3):336-40.
1992: Li X K; Lijnen H R; Nelles L; Hu M H; Collen D
Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
Biochimica et biophysica acta 1992;1159(1):37-43.
1992: Jang I K; Gold H K; Leinbach R C; Fallon J T; Collen D; Wilcox J N
Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1992;12(8):948-54.
1992: Dewerchin M; Vandamme A M; Holvoet P; De Cock F; Lemmens G; Lijnen H R; Stassen J M; Collen D
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Thrombosis and haemostasis 1992;68(2):170-9.
1992: Descheemaeker K A; Wyns S; Nelles L; Auwerx J; Ny T; Collen D
Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response.
The Journal of biological chemistry 1992;267(21):15086-91.
1992: Vaughan D E; Declerck P J; Van Houtte E; De Mol M; Collen D
Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
Thrombosis and haemostasis 1992;68(1):60-3.
1992: Imura Y; Stassen J M; Collen D
Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
The Journal of pharmacology and experimental therapeutics 1992;261(3):895-8.
1992: Declerck P J; De Mol M; Vaughan D E; Collen D
Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.
The Journal of biological chemistry 1992;267(17):11693-6.
1992: Lu H R; Gold H K; Wu Z; Yasuda T; Pauwels P; Rapold H J; Napier M; Bunting S; Collen D
G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
Thrombosis and haemostasis 1992;67(6):686-91.
1992: Rapold H J; Stassen T; Van de Werf F; Collen D
Comparative copper coil-induced thrombogenicity of the internal mammary, left anterior descending coronary, and popliteal arteries in dogs.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1992;12(5):639-44.
1992: Imura Y; Stassen J M; Kurokawa T; Iwasa S; Lijnen H R; Collen D
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
Blood 1992;79(9):2322-9.
1992: Lu H R; Wu Z; Pauwels P; Lijnen H R; Collen D
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Journal of the American College of Cardiology 1992;19(6):1350-9.
1992: Nelles L; Li X K; Vanlinthout I; De Cock F; Lijnen H R; Collen D
Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
Thrombosis and haemostasis 1992;67(4):445-52.
1992: Lijnen H R; Li X K; Nelles L; Hu M H; Collen D
Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
European journal of biochemistry / FEBS 1992;205(2):701-9.
1992: Bulens F; Nelles L; Van den Panhuyzen N; Collen D
Stimulation by retinoids of tissue-type plasminogen activator secretion in cultured human endothelial cells: relations of structure to effect.
Journal of cardiovascular pharmacology 1992;19(4):508-14.
1992: Vandamme A M; Dewerchin M; Lijnen H R; Bernar H; Bulens F; Nelles L; Collen D
Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
European journal of biochemistry / FEBS 1992;205(1):139-46.
1992: Rapold H J; de Bono D; Arnold A E; Arnout J; De Cock F; Collen D; Verstraete M
Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group.
Circulation 1992;85(3):928-34.
1992: Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen H R
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Thrombosis research 1992;65(3):421-38.
1992: Lijnen H R; Webb P D; Van Hoef B; De Cock F; Stassen J M; Prior S D; Collen D
Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
Thrombosis and haemostasis 1992;67(2):239-47.
1992: Li X K; Lijnen H R; Nelles L; Van Hoef B; Stassen J M; Collen D
Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Blood 1992;79(2):417-29.
1992: Lijnen H R; Van Hoef B; Matsuo O; Collen D
On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin.
Biochimica et biophysica acta 1992;1118(2):144-8.
1992: Collen D
Designing thrombolytic agents: focus on safety and efficacy.
The American journal of cardiology 1992;69(2):71A-81A.
1992: Declerck P J; Van Keer L; Verstreken M; Collen D
An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA.
Thrombosis and haemostasis 1992;67(1):95-100.
1992: Jacobs H; Van de Werf F; Lesaffre E; De Geest H; Collen D
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters.
Acta clinica Belgica 1992;47(2):82-9.
1991: Kurokawa T; Iwasa S; Kakinuma A; Stassen J M; Lijnen H R; Collen D
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Thrombosis and haemostasis 1991;66(6):684-93.
1991: Collen D; Lijnen H R
Basic and clinical aspects of fibrinolysis and thrombolysis.
Blood 1991;78(12):3114-24.
1991: Thompson E A; Nelles L; Collen D
Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cells.
European journal of biochemistry / FEBS 1991;201(3):627-32.
1991: Holvoet P; Laroche Y; Lijnen H R; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
The Journal of biological chemistry 1991;266(29):19717-24.
1991: Lijnen H R; Stassen J M; Vanlinthout I; Fukao H; Okada K; Matsuo O; Collen D
Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
Thrombosis and haemostasis 1991;66(4):468-73.
1991: Collen D; Lu H R; Lijnen H R; Nelles L; Stassen J M
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Circulation 1991;84(3):1216-34.
1991: Laroche Y; Demaeyer M; Stassen J M; Gansemans Y; Demarsin E; Matthyssens G; Collen D; Holvoet P
Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer.
The Journal of biological chemistry 1991;266(25):16343-9.
1991: Dewerchin M; Collen D
Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot-specific monoclonal antibodies.
Bioconjugate chemistry 1991;2(5):293-300.
1991: Dewerchin M; Lijnen H R; Stassen J M; De Cock F; Quertermous T; Ginsberg M H; Plow E F; Collen D
Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Blood 1991;78(4):1005-18.
1991: Vaughan D E; Van Houtte E; Declerck P J; Collen D
Streptokinase-induced platelet aggregation. Prevalence and mechanism.
Circulation 1991;84(1):84-91.
1991: Lu H R; Lijnen H R; Stassen J M; Collen D
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Blood 1991;78(1):125-31.
1991: Lijnen H R; Van Hoef B; De Cock F; Okada K; Ueshima S; Matsuo O; Collen D
On the mechanism of fibrin-specific plasminogen activation by staphylokinase.
The Journal of biological chemistry 1991;266(18):11826-32.
1991: Stassen J M; Lijnen H R; Kieckens L; Collen D
Small animal thrombosis models for the evaluation of thrombolytic agents.
Circulation 1991;83(6 Suppl):IV65-72.
1991: Gold H K; Yasuda T; Jang I K; Guerrero J L; Fallon J T; Leinbach R C; Collen D
Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Circulation 1991;83(6 Suppl):IV26-40.
1991: Declerck P J; Lijnen H R; Verstreken M; Collen D
Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.
Thrombosis and haemostasis 1991;65(4):394-8.
1991: Garabedian H D; Gold H K; Leinbach R C; Svizzero T A; Finkelstein D M; Guerrero J L; Collen D
Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin.
Journal of the American College of Cardiology 1991;17(5):1213-22.
1991: Lijnen H R; Collen D
Towards the development of improved thrombolytic agents.
British journal of haematology 1991;77(3):261-6.
1991: Lijnen H R; Van Hoef B; Collen D
On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
The Journal of biological chemistry 1991;266(7):4041-4.
1991: Yasuda T; Gold H K; Leinbach R C; Yaoita H; Fallon J T; Guerrero L; Napier M A; Bunting S; Collen D
Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
Circulation 1991;83(3):1038-47.
1991: Rapold H J; Lu H R; Wu Z M; Nijs H; Collen D
Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.
Blood 1991;77(5):1020-4.
1991: Collen D; Lijnen H R; Vanlinthout I; Kieckens L; Nelles L; Stassen J M
Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
Thrombosis and haemostasis 1991;65(2):174-80.
1991: Bulens F; Vandamme A M; Bernar H; Nelles L; Lijnen R H; Collen D
Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer.
European journal of biochemistry / FEBS 1991;195(1):235-42.
1991: Bartha K; Declerck P J; Moreau H; Nelles L; Collen D
Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. Effect of active site mutagenized tissue-type plasminogen activator.
The Journal of biological chemistry 1991;266(2):792-7.
1991: Lijnen H R; Collen D
New strategies in the development of thrombolytic agents.
Current studies in hematology and blood transfusion 1991;(58):69-72.
1991: Collen D; Lijnen H R
Thrombolytic therapy.
Annals of the New York Academy of Sciences 1991;614():259-69.
1990: Yasuda T; Gold H K; Leinbach R C; Saito T; Guerrero J L; Jang I K; Holt R; Fallon J T; Collen D
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
Journal of the American College of Cardiology 1990;16(7):1728-35.
1990: Jang I K; Gold H K; Leinbach R C; Fallon J T; Collen D
In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
Circulation research 1990;67(6):1552-61.
1990: Vaughan D E; Declerck P J; Van Houtte E; De Mol M; Collen D
Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo.
Circulation research 1990;67(5):1281-6.
1990: Collen D; Dewerchin M; Rapold H J; Lijnen H R; Stassen J M
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Circulation 1990;82(5):1744-53.
1990: Sabovic M; Lijnen H R; Keber D; Collen D
Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.
Thrombosis and haemostasis 1990;64(3):450-4.
1990: Rapold H J; Wu Z M; Stassen T; Van de Werf F; Collen D
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Blood 1990;76(8):1558-63.
1990: Vandamme A M; Bulens F; Bernar H; Nelles L; Lijnen R H; Collen D
Construction and characterization of a recombinant murine monoclonal antibody directed against human fibrin fragment-D dimer.
European journal of biochemistry / FEBS 1990;192(3):767-75.
1990: Yasuda T; Gold H K; Yaoita H; Leinbach R C; Guerrero J L; Jang I K; Holt R; Fallon J T; Collen D
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
Journal of the American College of Cardiology 1990;16(3):714-22.
1990: Gold H K; Gimple L W; Yasuda T; Leinbach R C; Werner W; Holt R; Jordan R; Berger H; Collen D; Coller B S
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
The Journal of clinical investigation 1990;86(2):651-9.
1990: Lijnen H R; Van Hoef B; De Cock F; Collen D
Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
Thrombosis and haemostasis 1990;64(1):61-8.
1990: Nelles L; Lijnen H R; Van Nuffelen A; Demarsin E; Collen D
Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Thrombosis and haemostasis 1990;64(1):53-60.
1990: Wu Z; Van de Werf F; Stassen T; Mattsson C; Pohl G; Collen D
Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model.
Journal of cardiovascular pharmacology 1990;16(2):197-203.
1990: Collen D; Lijnen H R
Molecular mechanisms of thrombolysis: implications for therapy.
Biochemical pharmacology 1990;40(2):177-86.
1990: Collen D; Lijnen H R; Bulens F; Vandamme A M; Tulinsky A; Nelles L
Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
The Journal of biological chemistry 1990;265(21):12184-91.
1990: Declerck P J; Lijnen H R; Verstreken M; Moreau H; Collen D
A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Blood 1990;75(9):1794-800.
1990: Lijnen H R; Nelles L; Van Hoef B; De Cock F; Collen D
Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
The Journal of biological chemistry 1990;265(10):5677-83.
1990: Collen D
Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
Annals of internal medicine 1990;112(7):529-38.
1990: Lijnen H R; Van Hoef B; Nelles L; Collen D
Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
The Journal of biological chemistry 1990;265(9):5232-6.
1990: Lijnen H R; Dewerchin M; De Cock F; Collen D
Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Thrombosis research 1990;57(3):333-42.
1990: Jang I K; Gold H K; Ziskind A A; Leinbach R C; Fallon J T; Collen D
Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Circulation 1990;81(1):219-25.
1990: Declerck P J; Collen D
Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays.
Thrombosis research. Supplement 1990;10():3-9.
1990: Collen D C; Gold H K
New developments in thrombolytic therapy.
Thrombosis research. Supplement 1990;10():105-31.
1990: Collen D; Gold H K
New developments in thrombolytic therapy.
Advances in experimental medicine and biology 1990;281():333-54.
1990: Lijnen H R; Van Hoef B; Collen D
On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen.
Thrombosis research. Supplement 1990;10():45-54.
1989: Sabovic M; Lijnen H R; Keber D; Collen D
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Thrombosis and haemostasis 1989;62(4):1083-7.
1989: Dewerchin M; Lijnen H R; Van Hoef B; De Cock F; Collen D
Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
European journal of biochemistry / FEBS 1989;185(1):141-9.
1989: Vaughan D E; Mendelsohn M E; Declerck P J; Van Houtte E; Collen D; Loscalzo J
Characterization of the binding of human tissue-type plasminogen activator to platelets.
The Journal of biological chemistry 1989;264(27):15869-74.
1989: Arnold A E; Brower R W; Collen D; van Es G A; Lubsen J; Serruys P W; Simoons M L; Verstraete M
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
Journal of the American College of Cardiology 1989;14(3):581-8.
1989: Gimple L W; Gold H K; Leinbach R C; Coller B S; Werner W; Yasuda T; Johns J A; Ziskind A A; Finkelstein D; Collen D
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Circulation 1989;80(3):581-8.
1989: Ballegeer V; Spitz B; Kieckens L; Moreau H; Van Assche A; Collen D
Predictive value of increased plasma levels of fibronectin in gestational hypertension.
American journal of obstetrics and gynecology 1989;161(2):432-6.
1989: Vaughan D E; Declerck P J; De Mol M; Collen D
Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.
The Journal of clinical investigation 1989;84(2):586-91.
1989: Lijnen H R; Van Hoef B; De Cock F; Collen D
The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
Blood 1989;73(7):1864-72.
1989: Yasuda T; Gold H K; Fallon J T; Leinbach R C; Garabedian H D; Guerrero J L; Collen D
A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
Journal of the American College of Cardiology 1989;13(6):1409-14.
1989: Hashimoto Y; Stassen J M; Leclef B; De Roo M; Vandecruys A; Melin J; Verhoeven-Mester D; Trouet A; Collen D
Thrombus imaging with an I-123-labeled F(ab')2 fragment of an anti-human fibrin monoclonal antibody in a rabbit model.
Radiology 1989;171(1):223-6.
1989: Holvoet P; Stassen J M; Hashimoto Y; Spriggs D; Devos P; Collen D
Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbits.
Thrombosis and haemostasis 1989;61(2):307-13.
1989: Spriggs D J; Stassen J M; Hashimoto Y; Collen D
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Blood 1989;73(5):1207-12.
1989: Jang I K; Gold H K; Ziskind A A; Fallon J T; Holt R E; Leinbach R C; May J W; Collen D
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
Circulation 1989;79(4):920-8.
1989: Spriggs D; Gold H K; Hashimoto Y; Van Houtte E; Vermylen J; Collen D
Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
Thrombosis and haemostasis 1989;61(1):93-6.
1989: Ziskind A A; Gold H K; Yasuda T; Kanke M; Guerrero J L; Fallon J T; Saito T; Collen D
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Circulation 1989;79(2):393-9.
1989: Lijnen H R; Collen D
Interaction of heparin with histidine-rich glycoprotein.
Annals of the New York Academy of Sciences 1989;556():181-5.
1988: Lijnen H R; Nelles L; Van Hoef B; Demarsin E; Collen D
Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
The Journal of biological chemistry 1988;263(35):19083-91.
1988: Lijnen H R; Nelles L; Van Hoef B; Demarsin E; Collen D
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
European journal of biochemistry / FEBS 1988;177(3):575-82.
1988: Lijnen H R; Nelles L; Van Hoef B; De Cock F; Collen D
Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Thrombosis and haemostasis 1988;60(2):247-50.
1988: Lijnen H R; Collen D
New strategies in the development of thrombolytic agents.
Blut 1988;57(4):147-62.
1988: Declerck P J; De Mol M; Alessi M C; Baudner S; Pâques E P; Preissner K T; Müller-Berghaus G; Collen D
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).
The Journal of biological chemistry 1988;263(30):15454-61.
1988: Johns J A; Gold H K; Leinbach R C; Yasuda T; Gimple L W; Werner W; Finkelstein D; Newell J; Ziskind A A; Collen D
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Circulation 1988;78(3):546-56.
1988: Alessi M C; Declerck P J; De Mol M; Nelles L; Collen D
Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).
European journal of biochemistry / FEBS 1988;175(3):531-40.
1988: Collen D
Fibrin-specific thrombolytic agents.
Archives des maladies du coeur et des vaisseaux 1988;81 Spec No():19-23.
1988: Collen D; Juhan-Vague I
Fibrinolysis and atherosclerosis.
Seminars in thrombosis and hemostasis 1988;14(2):180-3.
1988: Garabedian H D; Gold H K; Leinbach R C; Yasuda T; Johns J A; Thornton D; Collen D
Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator.
Thrombosis research 1988;50(1):121-33.
1988: Garabedian H D; Gold H K; Yasuda T; Johns J A; Finkelstein D M; Gaivin R J; Cobbaert C; Leinbach R C; Collen D
Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiography.
Journal of the American College of Cardiology 1988;11(4):729-34.
1988: Collen D
Synergism of thrombolytic agents: investigational procedures and clinical potential.
Circulation 1988;77(4):731-5.
1988: Lijnen H R; Nelles L; Holmes W E; Collen D
Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
The Journal of biological chemistry 1988;263(12):5594-8.
1988: Yasuda T; Gold H K; Fallon J T; Leinbach R C; Guerrero J L; Scudder L E; Kanke M; Shealy D; Ross M J; Collen D
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
The Journal of clinical investigation 1988;81(4):1284-91.
1988: Cambier P; van de Werf F; Larsen G R; Collen D
Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
Journal of cardiovascular pharmacology 1988;11(4):468-72.
1988: Gold H K; Coller B S; Yasuda T; Saito T; Fallon J T; Guerrero J L; Leinbach R C; Ziskind A A; Collen D
Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
Circulation 1988;77(3):670-7.
1988: Lijnen H R; Van Hoef B; Nelles L; Holmes W E; Collen D
Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator.
European journal of biochemistry / FEBS 1988;172(1):185-8.
1988: Declerck P J; Alessi M C; Verstreken M; Kruithof E K; Juhan-Vague I; Collen D
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.
Blood 1988;71(1):220-5.
1988: Collen D
Potential approaches for therapeutic intervention of thrombosis by fibrinolytic agents.
Seminars in thrombosis and hemostasis 1988;14(1):95-9.
1988: Collen D; Stassen J M; Larsen G
Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.
Blood 1988;71(1):216-9.
1988: Auwerx J; Bouillon R; Collen D; Geboers J
Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
Arteriosclerosis (Dallas, Tex.) 1988;8(1):68-72.
1988: Lijnen H R; Collen D
Mechanisms of plasminogen activation by mammalian plasminogen activators.
Enzyme 1988;40(2-3):90-6.
1988: Collen D; Stump D C; Gold H K
Thrombolytic therapy.
Annual review of medicine 1988;39():405-23.
1988: Verstraete M; Bory M; Collen D; Erbel R; Lennane R J; Mathey D; Michels H R; Schartl M; Uebis R; Bernard R
[Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator]
Klinische Wochenschrift 1988;66 Suppl 12():77-85.
1988: Collen D
Fibrin-specific thrombolytic agents.
Klinische Wochenschrift 1988;66 Suppl 12():15-23.
1988: Collen D
Fibrin-specific thrombolytic therapy.
Thrombosis research. Supplement 1988;8():3-14.
1988: Collen D
Fibrin-specific thrombolytic agents.
Annales de biologie clinique 1988;46(3):195-200.
1987: Ballegeer V; Mombaerts P; Declerck P J; Spitz B; Van Assche F A; Collen D
Fibrinolytic response to venous occlusion and fibrin fragment D-dimer levels in normal and complicated pregnancy.
Thrombosis and haemostasis 1987;58(4):1030-2.
1987: Declerck P J; Mombaerts P; Holvoet P; De Mol M; Collen D
Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.
Thrombosis and haemostasis 1987;58(4):1024-9.
1987: Lijnen H R; Van Hoef B; Collen D
Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
European journal of biochemistry / FEBS 1987;169(2):359-64.
1987: Collen D
Fibrin-specific thrombolytic agents.
Schweizerische medizinische Wochenschrift 1987;117(46):1791-8.
1987: Gold H K; Johns J A; Leinbach R C; Yasuda T; Collen D
Thrombolytic therapy for unstable angina pectoris: rationale and results.
Journal of the American College of Cardiology 1987;10(5 Suppl B):91B-95B.
1987: Collen D
Molecular mechanism of action of newer thrombolytic agents.
Journal of the American College of Cardiology 1987;10(5 Suppl B):11B-15B.
1987: Collen D; Stassen J M; De Cock F
Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Thrombosis and haemostasis 1987;58(3):943-6.
1987: Holmes W E; Lijnen H R; Nelles L; Kluft C; Nieuwenhuis H K; Rijken D C; Collen D
Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity.
Science (New York, N.Y.) 1987;238(4824):209-11.
1987: Stassen J M; Juhan-Vague I; Alessi M C; De Cock F; Collen D
Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
Thrombosis and haemostasis 1987;58(3):947-50.
1987: Verstraete M; Arnold A E; Brower R W; Collen D; de Bono D P; De Zwaan C; Erbel R; Hillis W S; Lennane R J; Lubsen J
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.
The American journal of cardiology 1987;60(4):231-7.
1987: Nelles L; Lijnen H R; Collen D; Holmes W E
Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
The Journal of biological chemistry 1987;262(22):10855-62.
1987: Holmes W E; Lijnen H R; Collen D
Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site.
Biochemistry 1987;26(16):5133-40.
1987: Lijnen H R; Holmes W E; van Hoef B; Wiman B; Rodriguez H; Collen D
Amino-acid sequence of human alpha 2-antiplasmin.
European journal of biochemistry / FEBS 1987;166(3):565-74.
1987: Gold H K; Johns J A; Leinbach R C; Yasuda T; Grossbard E; Zusman R; Collen D
A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.
Circulation 1987;75(6):1192-9.
1987: Nelles L; Lijnen H R; Collen D; Holmes W E
Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
The Journal of biological chemistry 1987;262(12):5682-9.
1987: Garabedian H D; Gold H K; Leinbach R C; Johns J A; Yasuda T; Kanke M; Collen D
Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
Journal of the American College of Cardiology 1987;9(3):599-607.
1987: Stump D C; Stassen J M; Demarsin E; Collen D
Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
Blood 1987;69(2):592-6.
1987: Holmes W E; Nelles L; Lijnen H R; Collen D
Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin).
The Journal of biological chemistry 1987;262(4):1659-64.
1986: Garabedian H D; Gold H K; Leinbach R C; Yasuda T; Johns J A; Collen D
Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis.
The American journal of cardiology 1986;58(9):673-9.
1986: Collen D; De Cock F; Demarsin E; Lijnen H R; Stump D C
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Thrombosis and haemostasis 1986;56(1):35-9.
1986: Gold H K; Leinbach R C; Garabedian H D; Yasuda T; Johns J A; Grossbard E B; Palacios I; Collen D
Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.
Circulation 1986;73(2):347-52.
1985: Verstraete M; Bleifeld W; Brower R W; Charbonnier B; Collen D; de Bono D P; Dunning A J; Lennane R J; Lubsen J; Mathey D G
Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction.
Lancet 1985;2(8462):965-9.
1985: Verstraete M; Bernard R; Bory M; Brower R W; Collen D; de Bono D P; Erbel R; Huhmann W; Lennane R J; Lubsen J
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.
Lancet 1985;1(8433):842-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Désiré Collen

Research Profile (preview)

Chemicals & Drugs

Living Beings

Physiology

Anatomy

Procedures

Concepts & Ideas

Disorders

Genes & Molecular Sequences

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Désiré Collen (preview)

All Publications